CONTRAFECT CORP
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CFRXQ and buy or sell other stocks, ETFs, and their options commission-free!About CFRXQ
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.
CEOMichael Messinger, CPA
CEOMichael Messinger, CPA
Employees23
Employees23
HeadquartersYonkers, New York
HeadquartersYonkers, New York
Founded2008
Founded2008
Employees23
Employees23
CFRXQ Key Statistics
Market cap1.07K
Market cap1.07K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume6.60
Average volume6.60
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.0001
52 Week high$0.0001
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
CONTRAFECT CORP(CFRXQ) stock is priced at $0.00, giving the company a market capitalization of 1.07K.
On 2026-11-08, CONTRAFECT CORP(CFRXQ) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for CONTRAFECT CORP(CFRXQ) stock has reached 0, versus its average volume of 6.6.
The stock's 52-week range extends from a low of $0.00 to a high of $0.00.
The stock's 52-week range extends from a low of $0.00 to a high of $0.00.
People also own
Based on the portfolios of people who own CFRXQ. This list is generated using Robinhood data, and it’s not a recommendation.